Biopharma companies are facing funding challenges in 2023 as interest rates rise and investors are becoming more risk adverse. There is hope on the horizon, say some...

Australian biopharma CSL said this week it has received all the regulatory clearance required to take over Switzerland’s Vifor. The acquisition announced in December 2021...

After days of speculation, it’s now official. Australian biopharmaceuticals manufacturer CSL has grabbed for and won the hand of Swiss Vifor Pharma. The boards of both...